Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11024614 | 0.80 | TAAR1 (0.66) | TAAR1HTR2AHTR2CIDO1LMNA | |
| SCHEMBL3008829 | 0.78 | SIGMAR1 (0.59) | TAAR1HTR2ALMNATSHRRECQL | |
| SCHEMBL28645729 | 0.75 | TAAR1 (0.64) | TAAR1HTR2AHTR2CIDO1POLB | |
| SCHEMBL3056754 | 0.72 | TAAR1 (1.00) | TAAR1HTTHTR2AIDO1LMNA | |
| SCHEMBL9331124 | 0.72 | TAAR1 (0.58) | TAAR1IDO1LMNATSHRALDH1A1 | |
| SCHEMBL239490 | 0.71 | ALDH1A1 (0.45) | POLBTSHRKDM4ERECQLSMN1; SMN2 | |
| SCHEMBL3005665 | 0.70 | MPO (0.64) | TAAR1HTR2APOLBGAAKDM4E | |
| SCHEMBL11894723 | 0.70 | DRD4 (0.69) | GAAKDM4ERECQLSMN1; SMN2 | |
| SCHEMBL9419149 | 0.70 | IDO1 (0.59) | TAAR1HPGDHTTIDO1LMNA | |
| SCHEMBL30436408 | 0.69 | TAAR1 (0.60) | TAAR1HPGDIDO1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372864-B2 | 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2013-02-12 | — | — | US | disclosed |
| US-20100197725-A1 | 1-OXO-ISOINDOLINE-4-CARBOXAMIDE AND 1-OXO-1,2,3,4-TETRAHYDROISOQUINOLINE-5-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197725-A1 | 1-OXO-ISOINDOLINE-4-CARBOXAMIDE AND 1-OXO-1,2,3,4-TETRAHYDROISOQUINOLINE-5-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | COX4I1, CNR2, CNR1 | TAAR1 1133/4885HPGD 917/4885HTT 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.